La pharmacorésistance aux psychotropes chez l’enfant et l’adolescent : recherche d’anomalies pharmacogénétiques du cytochrome P450 2D6
- 1 June 2021
- journal article
- research article
- Published by Elsevier BV in L'Encéphale
- Vol. 47 (3), 227-234
- https://doi.org/10.1016/j.encep.2020.09.010
Abstract
No abstract availableKeywords
Funding Information
- Centre Hospitalier Universitaire de Nice
This publication has 27 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic AntidepressantsClinical Pharmacology & Therapeutics, 2013
- Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendationPsychiatry Research, 2012
- Therapeutic options in treatment-resistant depressionAnnals of Medicine, 2011
- Drug-Metabolizing Enzyme Genotypes and Aggressive Behavior Treatment Response in Hospitalized Pediatric Psychiatric PatientsJournal of Child and Adolescent Psychopharmacology, 2009
- Pharmacoepidemiology and Pediatric Psychopharmacology ResearchJournal of Child and Adolescent Psychopharmacology, 2005
- Recent Child Pharmacoepidemiological FindingsJournal of Child and Adolescent Psychopharmacology, 2005
- Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian populationPharmacological Research, 2004
- Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot studyEuropean Journal of Clinical Pharmacology, 2003
- Fluoxetine-Related Death in a Child with Cytochrome P-450 2D6 Genetic DeficiencyJournal of Child and Adolescent Psychopharmacology, 2000
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998